8-K: BioCryst Gains FDA Nod for ORLADEYO Oral Pellets in Kids

BioCryst Pharmaceuticals receives FDA approval for its ORLADEYO oral pellet formulation, expanding its use to pediatric patients aged 2 to less than 12 years with hereditary angioedema.

Summary

• The U.S. Food and Drug Administration (FDA) has approved BioCryst Pharmaceuticals' New Drug Application (NDA) for an oral pellet formulation of once-daily ORLADEYO (berotralstat).
• This approval is for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to less than 12 years.
• ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above.
• The capsule formulation of ORLADEYO was previously approved by the FDA in December 2020 for patients 12 years and older and is approved in over 45 countries.
• The approval is supported by positive interim data from the APeX-P clinical trial, which showed ORLADEYO was well tolerated, had a consistent safety profile, and resulted in early and sustained reductions in monthly attack rates in this age group.
• The oral pellet formulation is designed to be child-friendly, sprinkle-like in appearance, and can be swallowed with water or milk, or sprinkled over soft, non-acidic food.
• BioCryst has filed applications for ORLADEYO oral pellets with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency, with additional regulatory filings planned globally, including Canada.

Sentiment

Score: 9

Explanation: The FDA approval for a new, vulnerable patient population with a child-friendly formulation is a highly positive development, addressing an unmet need and expanding market potential for a key drug. This is a significant milestone for BioCryst.

Positives

• FDA approval expands ORLADEYO's market to a younger, vulnerable pediatric population (2 to <12 years) with HAE.
• ORLADEYO oral pellets are the first and only targeted oral prophylactic treatment option for this age group, addressing a significant unmet medical need.
• The child-friendly oral pellet formulation offers a less burdensome alternative to intravenous or subcutaneous injections for young patients and caregivers.
• Clinical trial data (APeX-P) demonstrated consistent safety and efficacy, with early and sustained reductions in HAE attack rates.
• The approval reinforces ORLADEYO's position as a leading HAE prophylactic therapy, now covering patients aged 2 and older.
• Global regulatory filings are underway in Europe, Japan, and Canada, indicating potential for further market expansion.

Risks

• BioCryst's ability to successfully implement its commercialization plans for the ORLADEYO oral pellets.
• The commercial viability of ORLADEYO oral pellets, including its ability to achieve market acceptance.
• Interim results of a clinical trial do not necessarily predict final results.
• Risks related to government actions, including that decisions and other actions may not be taken when expected or at all, or that the outcomes may not align with BioCryst's current expectations.
• Other applicable regulatory agencies may not approve ORLADEYO for use in pediatric patients with HAE aged 2 to <12 years within the expected timeframe, or at all.
• Regulatory agencies may determine deficiencies in the development program, require additional information or studies, disagree with safety and efficacy conclusions, impose restrictions, or delay/withhold market approval.
• Once approved, the FDA and other applicable regulatory agencies may withdraw market approval for ORLADEYO.

Future Outlook

BioCryst expects to successfully implement commercialization plans for ORLADEYO oral pellets and anticipates further global regulatory approvals in territories like Europe, Japan, and Canada. The company believes this approval will transform care for younger HAE patients, offering them more freedom to live a normal life.

Management Comments

• "Todays pediatric approval of ORLADEYO offers a welcome oral preventive choice for children living with HAE and provides families and clinicians with an important option for shared decision-making that matches treatment with patient needs." Anthony J. Castaldo, CEO and chairman of the U.S. Hereditary Angioedema Association (HAEA).
• "As we mark five years since ORLADEYO first transformed care for those with HAE ages 12 and older, this approval extends the benefits of oral prophylactic therapy to a vulnerable and important part of the HAE community, children ages 2 to less than 12. We couldnt be more excited to bring this treatment option to these kids and their caregivers." Jon Stonehouse, chief executive officer of BioCryst.
• "ORLADEYO has been prescribed to more than 3,500 patients in the U.S. to date, and were honored to now bring an oral pellet formulation to children and their caregivers, answering the communitys heartfelt call for a long-term prophylactic treatment option that meets the unique needs of children." Jon Stonehouse, chief executive officer of BioCryst.
• "This new oral pellet formulation of ORLADEYO provides a more easily administered long-term-prophylactic option to help children with HAE better manage their disease, especially when the experience of infusions or injections is not ideal." Dr. Raffi Tachdjian, Associate Clinical Professor of Medicine & Pediatrics, UCLA.
• "ORLADEYO oral pellets have the potential to change how a new generation of children with HAE and their caregivers manage this condition, giving them more freedom to live a normal life." Charlie Gayer, president & chief commercial officer of BioCryst.

Industry Context

This FDA approval positions BioCryst as a leader in the hereditary angioedema (HAE) treatment landscape, particularly for pediatric patients. By offering the first and only oral prophylactic therapy for children aged 2 to <12 years, BioCryst addresses a significant unmet need, as previous targeted treatments for this age group were limited to intravenous or subcutaneous injections. This innovation could shift treatment paradigms, making long-term prophylaxis more accessible and less burdensome for younger patients and their families, potentially increasing market share in the competitive HAE therapeutic space.

Comparison to Industry Standards

• ORLADEYO oral pellets are the first and only targeted oral prophylactic therapy for HAE patients aged 2 to <12 years, setting a new standard for convenience and patient-friendly administration in this specific demographic.
• Existing targeted treatment options for HAE patients under 12 years were previously limited to intravenous or subcutaneous injections, making ORLADEYO's oral pellet formulation a significant advancement compared to these more invasive methods.
• The APeX-P clinical trial, which supported this approval, is noted as the largest trial to date evaluating a long-term prophylactic therapy for HAE in patients 2 to <12 years of age, demonstrating BioCryst's commitment to robust clinical evidence in this underserved population.

Stakeholder Impact

• **Shareholders**: Positive impact due to expanded market opportunity, potential for increased revenue, and strengthened competitive position for ORLADEYO.
• **Patients (2 to <12 years with HAE)**: Significant positive impact by providing the first and only oral, child-friendly prophylactic treatment, reducing the burden of injections/infusions and improving quality of life.
• **Caregivers**: Positive impact by offering an easier and less stressful method of administering prophylactic therapy to young children.
• **Healthcare Professionals**: Provides an important new oral option for shared decision-making in managing HAE in pediatric patients, potentially improving treatment adherence.
• **Employees**: Positive impact through the successful development and commercialization of a new product formulation, reinforcing the company's mission and potentially leading to growth opportunities.

Next Steps

• Successfully implement commercialization plans for ORLADEYO oral pellets in the U.S.
• Pursue regulatory approvals for ORLADEYO oral pellets with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency.
• Plan additional regulatory filings in other global territories, including Canada.

Key Dates

Recommendation

The FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years represents a significant expansion of BioCryst's addressable market and a substantial competitive advantage. As the first and only oral prophylactic treatment for this vulnerable population, it addresses a critical unmet need and is likely to drive increased adoption and revenue. The child-friendly formulation enhances patient and caregiver convenience, which should support strong market penetration. This milestone, coupled with ongoing global regulatory filings, positions BioCryst for robust growth and strengthens its leadership in the HAE therapeutic space, making it a strong buy for investors.

Keywords

BioCryst Pharmaceuticals, ORLADEYO, berotralstat, FDA approval, hereditary angioedema, HAE, pediatric HAE, oral pellets, prophylactic therapy, rare disease, biotechnology, pharmaceuticals